It is widely acknowledged that cisplatin is transported mainly through the plasma membrane transporter called hCtr1 (23, 37), suggesting that the resistant cancer cells which express low level of hCtr1 would limit the amount of cisplatin enter the ovarian cancer cells. This evidence concerns the gene SLC31A1 and ovarian carcinoma.